Sitagliptin Phosphate Anhydrous represents a pharmaceutically optimised salt form in which counter-ion selection modifies the physicochemical properties of the parent molecule without altering its core pharmacophore or intrinsic pharmacodynamic activity. The crystal lattice energy of Sitagliptin Phosphate Anhydrous determines its thermodynamic stability, dissolution behaviour, and susceptibility to polymorphic transformation under manufacturing process conditions. PDE assessment for Sitagliptin Phosphate Anhydrous in shared manufacturing facilities is based on the pharmacological activity of the parent active moiety, with the MACO calculation adjusted using the molecular weight ratio of free base or acid to salt form.
The pharmacologically-based OEL approach is used for Sitagliptin Phosphate Anhydrous when its receptor-mediated pharmacodynamic activity in humans produces the most sensitive adverse effect at doses below the NOAEL from general organ toxicity studies.
